STOCK TITAN

CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

CytoSorbents (NASDAQ: CTSO), a specialist in blood purification for critical care and cardiac surgery, has announced plans to conduct in-person investor meetings in San Francisco during the 43rd Annual J.P. Morgan Healthcare Conference from January 13-15, 2025. The meetings will be coordinated by ICR Healthcare, offering investors the opportunity to meet with CEO Dr. Phillip Chan and CFO Peter J. Mariani. Interested parties can schedule meetings by contacting ICR Healthcare at ir@cytosorbents.com.

CytoSorbents (NASDAQ: CTSO), specializzata nella purificazione del sangue per cure critiche e interventi cardiaci, ha annunciato piani per condurre incontri dal vivo con gli investitori a San Francisco durante la 43ª Conferenza Annuale J.P. Morgan Healthcare dal 13 al 15 gennaio 2025. Gli incontri saranno coordinati da ICR Healthcare, offrendo agli investitori l'opportunità di incontrare il CEO Dr. Phillip Chan e il CFO Peter J. Mariani. Le parti interessate possono pianificare incontri contattando ICR Healthcare all'indirizzo ir@cytosorbents.com.

CytoSorbents (NASDAQ: CTSO), especialista en purificación de sangre para cuidados críticos y cirugía cardíaca, ha anunciado planes para llevar a cabo reuniones en persona con inversores en San Francisco durante la 43ª Conferencia Anual de Atención Médica de J.P. Morgan del 13 al 15 de enero de 2025. Las reuniones serán coordinadas por ICR Healthcare, ofreciendo a los inversores la oportunidad de reunirse con el CEO Dr. Phillip Chan y el CFO Peter J. Mariani. Las partes interesadas pueden programar reuniones contactando a ICR Healthcare en ir@cytosorbents.com.

CytoSorbents (NASDAQ: CTSO)는 중환자 치료 및 심장 수술을 위한 혈액 정화 전문 회사로서, 2025년 1월 13일부터 15일까지 열리는 제43회 J.P. Morgan Healthcare 콘퍼런스 기간 동안 샌프란시스코에서 대면 투자자 회의를 개최할 계획을 발표했습니다. 이 회의는 ICR Healthcare가 조율하여, 투자자들에게 CEO Dr. Phillip Chan과 CFO Peter J. Mariani를 만날 기회를 제공할 것입니다. 관심 있는 분들은 ir@cytosorbents.com으로 ICR Healthcare에 연락하여 회의를 예약할 수 있습니다.

CytoSorbents (NASDAQ: CTSO), un spécialiste de la purification du sang pour les soins critiques et la chirurgie cardiaque, a annoncé des projets pour organiser des réunions en personne avec des investisseurs à San Francisco lors de la 43ème Conférence Annuelle de Santé de J.P. Morgan du 13 au 15 janvier 2025. Les réunions seront coordonnées par ICR Healthcare, offrant aux investisseurs l'opportunité de rencontrer le PDG Dr. Phillip Chan et le CFO Peter J. Mariani. Les parties intéressées peuvent planifier des réunions en contactant ICR Healthcare à l'adresse ir@cytosorbents.com.

CytoSorbents (NASDAQ: CTSO), ein Spezialist für Blutreinigung in der Intensivmedizin und Herzchirurgie, hat Pläne angekündigt, persönliche Investorenmeetings in San Francisco während der 43. jährlichen J.P. Morgan Healthcare-Konferenz vom 13. bis 15. Januar 2025 abzuhalten. Die Meetings werden von ICR Healthcare koordiniert und bieten Investoren die Möglichkeit, CEO Dr. Phillip Chan und CFO Peter J. Mariani zu treffen. Interessierte Parteien können Meetings vereinbaren, indem sie ICR Healthcare unter ir@cytosorbents.com kontaktieren.

Positive
  • None.
Negative
  • None.

PRINCETON, N.J., Dec. 12, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today that management will host in-person investors meetings in San Francisco alongside the 43rd Annual J.P. Morgan Healthcare Conference being held January 13-15, 2025, in San Francisco, CA.

ICR Healthcare is coordinating meetings on the Company’s behalf. To schedule a meeting with Dr. Phillip Chan, Chief Executive Officer, and Peter J. Mariani, Chief Financial Officer, please send requests to ICR Healthcare at ir@cytosorbents.com.

About CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents’ proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, ECMO, heart-lung machines). CytoSorbents’ technologies are used in a number of broad applications. Specifically, two important applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding and 2) the removal of inflammatory agents in common critical illnesses such as sepsis, burn injury, trauma, lung injury, liver failure, cytokine release syndrome, and pancreatitis that can lead to massive inflammation, organ failure and patient death. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments.

CytoSorbents’ lead product, CytoSorb®, is approved in the European Union and distributed in 76 countries worldwide, with more than 250,000 devices used cumulatively to date. CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure, to reduce pro-inflammatory cytokine levels. CytoSorb is not yet approved in the United States.

In the U.S. and Canada, CytoSorbents is developing the DrugSorb™-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. It has received two FDA Breakthrough Device Designations: one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic procedures. In September 2024, the Company submitted a De Novo medical device application to the U.S. FDA requesting marketing approval to reduce the severity of perioperative bleeding in CABG patients on the antithrombotic drug ticagrelor, which was accepted for substantive review in October 2024. In November 2024, the Company received its Medical Device Single Audit Program (MDSAP) certification and submitted its Medical Device License (MDL) application to Health Canada. DrugSorb-ATR is not yet granted or approved in the United States and Canada, respectively.

The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, ContrastSorb, and others. For more information, please visit the Company’s website at www.cytosorbents.com or follow us on Facebook and X

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 14, 2024, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

U.S. Company Contact:
Peter J. Mariani, Chief Financial Officer
305 College Road East
Princeton, NJ 08540
pmariani@cytosorbents.com

Investor Relations Contact:
Aman Patel, CFA
ICR Healthcare
ir@cytosorbents.com


FAQ

When and where will CytoSorbents (CTSO) host investor meetings during JPM Healthcare Conference 2025?

CytoSorbents will host investor meetings in San Francisco alongside the J.P. Morgan Healthcare Conference from January 13-15, 2025.

How can investors schedule meetings with CytoSorbents (CTSO) management during the 2025 JPM Healthcare Conference?

Investors can schedule meetings by sending requests to ICR Healthcare at ir@cytosorbents.com.

Which CytoSorbents (CTSO) executives will be available for meetings at the 2025 JPM Healthcare Conference?

CEO Dr. Phillip Chan and CFO Peter J. Mariani will be available for investor meetings.

Who is coordinating CytoSorbents (CTSO) investor meetings at the 2025 JPM Healthcare Conference?

ICR Healthcare is coordinating the investor meetings on behalf of CytoSorbents.

Cytosorbents Corp.

NASDAQ:CTSO

CTSO Rankings

CTSO Latest News

CTSO Stock Data

49.46M
52.69M
3.82%
33.38%
2.38%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
PRINCETON